Rapt Therapeutics Inc (OQ:RAPT)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 561 Eccles Ave
SOUTH SAN FRANCISCO CA 94080-1906
Tel: N/A
Website: https://rapt.com
IR: See website
<
Key People
Brian Wong
President, Chief Executive Officer, Director
Rodney K. B. Young
Chief Financial Officer
Dirk Brockstedt
Chief Scientific Officer
Michael Listgarten
General Counsel
William Ho
Chief Medical Officer
 
Business Overview
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.
Financial Overview
For the fiscal year ended 31 December 2023, Rapt Therapeutics Inc revenues decreased from $1.5M to $0K. Net loss increased 39% to $116.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 50% to $93.1M (expense), Stock-based Compensation in SGA increase of 51% to $9.2M (expense).
Employees: 131 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $114.66M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$125.81M as of Dec 31, 2023
Net annual income (TTM): -$116.80M as of Dec 31, 2023
Free cash flow (TTM): -$98.17M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 34,799,702 as of Mar 28, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.